PATHOPHYSIOLOGY AND CLINICAL ASPECTS OF GRAVES' ORBITOPATHY: AN ANALYSIS OF THE CURRENT STATE OF KNOWLEDGE AND THERAPEUTIC TRENDS
DOI:
https://doi.org/10.31435/ijitss.4(52).2026.6272Keywords:
TSH Receptor Antibodies, Biological Therapy, Thyroid Eye Disease, Hyperthyroidism, Orbital InflammationAbstract
Graves’ orbitopathy (GO), also referred to as thyroid eye disease (TED) or endocrine orbitopathy (EO), is the most common extrathyroidal manifestation of Graves’ disease, affecting approximately 25–40% of patients. The pathogenesis of GO is complex and multifactorial, primarily involving autoimmune processes driven by antibodies against the thyrotropin receptor. These antibodies interact with both the TSH receptor and the insulin-like growth factor 1 receptor, leading to the activation of orbital fibroblasts, which results in chronic inflammation, soft tissue swelling, and fibrosis. The clinical presentation varies from mild symptoms to severe complications, such as dysthyroid optic neuropathy. Smoking remains the most critical modifiable risk factor, significantly worsening prognosis and reducing treatment efficacy. Diagnosis relies on a comprehensive assessment, including the Clinical Activity Score, laboratory evaluation of TRAb levels, and orbital imaging to determine disease activity and severity. Treatment strategies depend on the clinical phase: intravenous glucocorticosteroids are the first-line therapy for active moderate-to-severe disease, while modern biological therapies are increasingly used for refractory cases. In the inactive phase, surgical and rehabilitative interventions are primarily indicated. Due to the potential for relapse and the impact on quality of life, a multidisciplinary approach involving endocrinologists and ophthalmologists is essential for long-term management and improved patient outcomes.
References
Bartalena, L., Piantanida, E., Gallo, D., Lai, A., & Tanda, M. L. (2020). Epidemiology, natural history, risk factors, and prevention of Graves' orbitopathy. Frontiers in endocrinology, 11, 615993. https://doi.org/10.3389/fendo.2020.615993
Bartalena, L., & Tanda, M. L. (2022). Current concepts regarding Graves' orbitopathy. Journal of internal medicine, 292(5), 692–716. https://doi.org/10.1111/joim.13524
Bartalena, L., Kahaly, G. J., Baldeschi, L., Dayan, C. M., Eckstein, A., Marcocci, C., Marinò, M., Vaidya, B., Wiersinga, W. M., & EUGOGO † (2021). The 2021 European group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy. European journal of endocrinology, 185(4), G43–G67. https://doi.org/10.1530/EJE-21-0479
Bahn R. S. (2010). Graves' ophthalmopathy. The New England journal of medicine, 362(8), 726–738. https://doi.org/10.1056/NEJMra0905750
Wiersinga, W., Žarković, M., Bartalena, L., Donati, S., Perros, P., Okosieme, O., Morris, D., Fichter, N., Lareida, J., von Arx, G., Daumerie, C., Burlacu, M. C., Kahaly, G., Pitz, S., Beleslin, B., Ćirić, J., Ayvaz, G., Konuk, O., Törüner, F. B., Salvi, M., … EUGOGO (European Group on Graves’ Orbitopathy) (2018). Predictive score for the development or progression of Graves' orbitopathy in patients with newly diagnosed Graves' hyperthyroidism. European journal of endocrinology, 178(6), 635–643. https://doi.org/10.1530/EJE-18-0039
Bartalena, L., & Wiersinga, W. M. (2020). Proposal for standardization of primary and secondary outcomes in patients with active, moderate-to-severe Graves' orbitopathy. European thyroid journal, 9(Suppl 1), 3–16. https://doi.org/10.1159/000510700
Zhang, L., Baker, G., Janus, D., Paddon, C. A., Fuhrer, D., & Ludgate, M. (2006). Biological effects of thyrotropin receptor activation on human orbital preadipocytes. Investigative ophthalmology & visual science, 47(12), 5197–5203. https://doi.org/10.1167/iovs.06-0596
Wiersinga, W. M., Eckstein, A. K., & Žarković, M. (2025). Thyroid eye disease (Graves' orbitopathy): Clinical presentation, epidemiology, pathogenesis, and management. The lancet. Diabetes & endocrinology, 13(7), 600–614. https://doi.org/10.1016/S2213-8587(25)00066-X
Tsui, S., Naik, V., Hoa, N., Hwang, C. J., Afifiyan, N. F., Sinha Hikim, A., Gianoukakis, A. G., Douglas, R. S., & Smith, T. J. (2008). Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: A tale of two antigens implicated in Graves' disease. Journal of immunology (Baltimore, Md.: 1950), 181(6), 4397–4405. https://doi.org/10.4049/jimmunol.181.6.4397
Smith, T. J., & Janssen, J. A. M. J. L. (2019). Insulin-like growth factor-i receptor and thyroid-associated ophthalmopathy. Endocrine reviews, 40(1), 236–267. https://doi.org/10.1210/er.2018-00066
Krieger, C. C., Morgan, S. J., Neumann, S., & Gershengorn, M. C. (2018). Thyroid stimulating hormone (tsh)/insulin-like growth factor 1 (IGF1) receptor cross-talk in human cells. Current opinion in endocrine and metabolic research, 2, 29–33. https://doi.org/10.1016/j.coemr.2018.01.007
Eckstein, A. K., Lösch, C., Glowacka, D., Schott, M., Mann, K., Esser, J., & Morgenthaler, N. G. (2009). Euthyroid and primarily hypothyroid patients develop milder and significantly more asymmetrical graves ophthalmopathy. The British journal of ophthalmology, 93(8), 1052–1056. https://doi.org/10.1136/bjo.2007.137265
Wang, Y., Patel, A., & Douglas, R. S. (2019). Thyroid eye disease: How a novel therapy may change the treatment paradigm. Therapeutics and clinical risk management, 15, 1305–1318. https://doi.org/10.2147/TCRM.S193018
Eckstein, A., Quadbeck, B., Mueller, G., Rettenmeier, A. W., Hoermann, R., Mann, K., Steuhl, P., & Esser, J. (2003). Impact of smoking on the response to treatment of thyroid associated ophthalmopathy. The British journal of ophthalmology, 87(6), 773–776. https://doi.org/10.1136/bjo.87.6.773
Prummel, M. F., & Wiersinga, W. M. (1993). Smoking and risk of Graves' disease. JAMA, 269(4), 479–482.
Oeverhaus, M., Neumann, I., Chen, Y., & Eckstein, A. (2024). Endokrine orbitopathie als ursache einer diplopie im senium – unterschiede zwischen jung und alt [Graves' orbitopathy as the cause of diplopia in old age-differences between young and old]. Die Ophthalmologie, 121(7), 548–553. https://doi.org/10.1007/s00347-024-02073-x
Ahn, H. Y., Lee, J., Kim, M., & Lee, J. K. (2025). Risk factors and outcomes of Graves' orbitopathy after radioactive iodine therapy. Endocrine, 90(1), 248–255. https://doi.org/10.1007/s12020-025-04350-4
Tallstedt, L., Lundell, G., Tørring, O., Wallin, G., Ljunggren, J. G., Blomgren, H., & Taube, A. (1992). Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. The Thyroid Study Group. The New England journal of medicine, 326(26), 1733–1738. https://doi.org/10.1056/NEJM199206253262603
Lee, J., Kang, J., Ahn, H. Y., & Lee, J. K. (2023). Sex-specific risk factors associated with graves' orbitopathy in Korean patients with newly diagnosed graves' disease. Eye (London, England), 37(16), 3382–3391. https://doi.org/10.1038/s41433-023-02513-z
Prummel, M. F., Wiersinga, W. M., Mourits, M. P., Koornneef, L., Berghout, A., & van der Gaag, R. (1990). Effect of abnormal thyroid function on the severity of Graves' ophthalmopathy. Archives of internal medicine, 150(5), 1098–1101.
Gorman C. (1983). Ophthalmopathy of Graves' disease. The New England journal of medicine, 308(8), 453–454. https://doi.org/10.1056/NEJM198302243080811
Bartley G. B. (1994). The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in olmsted county, minnesota. Transactions of the American Ophthalmological Society, 92, 477–588.
Wiersinga, W. M., Smit, T., van der Gaag, R., & Koornneef, L. (1988). Temporal relationship between onset of Graves' ophthalmopathy and onset of thyroidal Graves' disease. Journal of endocrinological investigation, 11(8), 615–619. https://doi.org/10.1007/BF03350193
Enzmann, D. R., Donaldson, S. S., & Kriss, J. P. (1979). Appearance of Graves' disease on orbital computed tomography. Journal of computer assisted tomography, 3(6), 815–819.
Wiersinga, W. M., Smit, T., van der Gaag, R., Mourits, M., & Koornneef, L. (1989). Clinical presentation of Graves' ophthalmopathy. Ophthalmic research, 21(2), 73–82. https://doi.org/10.1159/000266782
Marcocci, C., Bartalena, L., Bogazzi, F., Panicucci, M., & Pinchera, A. (1989). Studies on the occurrence of ophthalmopathy in Graves' disease. Acta endocrinologica, 120(4), 473–478. https://doi.org/10.1530/acta.0.1200473
McCord C. D., Jr (1981). Orbital decompression for Graves' disease. Exposure through lateral canthal and inferior fornix incision. Ophthalmology, 88(6), 533–541.
Perros, P., & Kendall-Taylor, P. (1992). Pathogenetic mechanisms in thyroid-associated ophthalmopathy. Journal of internal medicine, 231(3), 205–211. https://doi.org/10.1111/j.1365-2796.1992.tb00525.x
Cheng, J., Zhang, X., Lian, J., Piao, Z., Zhou, L., Gou, X., Chen, C., Chen, L., Jiang, K., Cheng, J., Ji, L., & Hong, N. (2023). Evaluation of activity of Graves' orbitopathy with multiparameter orbital magnetic resonance imaging (MRI). Quantitative imaging in medicine and surgery, 13(5), 3040–3049. https://doi.org/10.21037/qims-22-814
Alsuhaibani, A. H., & Nerad, J. A. (2007). Thyroid-associated orbitopathy. Seminars in plastic surgery, 21(1), 65–73. https://doi.org/10.1055/s-2007-967751
Kahaly, G.J. (2001). Imaging in thyroid-associated orbitopathy. European journal of endocrinology, 145(2), 107–18.
Bartalena, L., Marcocci, C., Tanda, M. L., Manetti, L., Dell'Unto, E., Bartolomei, M. P., Nardi, M., Martino, E., & Pinchera, A. (1998). Cigarette smoking and treatment outcomes in graves ophthalmopathy. Annals of internal medicine, 129(8), 632–635. https://doi.org/10.7326/0003-4819-129-8-199810150-00010
Khong, J. J., Finch, S., De Silva, C., Rylander, S., Craig, J. E., Selva, D., & Ebeling, P. R. (2016). Risk factors for Graves' orbitopathy; the Australian thyroid-associated orbitopathy research (ATOR) study. The Journal of clinical endocrinology and metabolism, 101(7), 2711–2720. https://doi.org/10.1210/jc.2015-4294
Weissel M. (2011). Selenium and the course of mild Graves' orbitopathy. The New England journal of medicine, 365(8), 769–771. https://doi.org/10.1056/NEJMc1107080
van Geest, R. J., Sasim, I. V., Koppeschaar, H. P., Kalmann, R., Stravers, S. N., Bijlsma, W. R., & Mourits, M. P. (2008). Methylprednisolone pulse therapy for patients with moderately severe Graves' orbitopathy: A prospective, randomized, placebo-controlled study. European journal of endocrinology, 158(2), 229–237. https://doi.org/10.1530/EJE-07-0558
Kahaly, G. J., Pitz, S., Hommel, G., & Dittmar, M. (2005). Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves' orbitopathy. The Journal of clinical endocrinology and metabolism, 90(9), 5234–5240. https://doi.org/10.1210/jc.2005-0148
Nedeljkovic Beleslin, B., Ciric, J., Stojkovic, M., Savic, S., Lalic, T., Stojanovic, M., Miletic, M., Knezevic, M., Stankovic, B., & Zarkovic, M. (2020). Comparison of efficacy and safety of parenteral versus parenteral and oral glucocorticoid therapy in Graves' orbitopathy. International journal of clinical practice, 74(11), e13608. https://doi.org/10.1111/ijcp.13608
Allison, A. C., & Eugui, E. M. (2000). Mycophenolate mofetil and its mechanisms of action. Immunopharmacology, 47(2-3), 85–118. https://doi.org/10.1016/s0162-3109(00)00188-0
Feng, W., Hu, Y., Zhang, C., Shi, H., Zhang, P., Yang, Y., Chen, S., Cui, W., & Cui, D. (2022). Efficacy and safety of mycophenolate mofetil in the treatment of moderate to severe Graves' orbitopathy: A meta-analysis. Bioengineered, 13(6), 14719–14729. https://doi.org/10.1080/21655979.2022.2101191
Utech, C., Wulle, K. G., Bieler, E. U., Pfannenstiel, P., Panitz, N., & Kiefer, H. (1985). Treatment of severe Graves' ophthalmopathy with cyclosporin a. Acta endocrinologica, 110(4), 493–498. https://doi.org/10.1530/acta.0.1100493
Chalvatzis, N. T., Tzamalis, A. K., Kalantzis, G. K., El-Hindy, N., Dimitrakos, S. A., & Potts, M. J. (2014). Safety and efficacy of combined immunosuppression and orbital radiotherapy in thyroid-related restrictive myopathy: Two-center experience. European journal of ophthalmology, 24(6), 953–959. https://doi.org/10.5301/ejo.5000463
Perros, P., Weightman, D. R., Crombie, A. L., & Kendall-Taylor, P. (1990). Azathioprine in the treatment of thyroid-associated ophthalmopathy. Acta endocrinologica, 122(1), 8–12. https://doi.org/10.1530/acta.0.1220008
Smith, T. J., Kahaly, G. J., Ezra, D. G., Fleming, J. C., Dailey, R. A., Tang, R. A., Harris, G. J., Antonelli, A., Salvi, M., Goldberg, R. A., Gigantelli, J. W., Couch, S. M., Shriver, E. M., Hayek, B. R., Hink, E. M., Woodward, R. M., Gabriel, K., Magni, G., & Douglas, R. S. (2017). Teprotumumab for thyroid-associated ophthalmopathy. The New England journal of medicine, 376(18), 1748–1761. https://doi.org/10.1056/NEJMoa1614949
Neag, E. J., & Smith, T. J. (2022). 2021 update on thyroid-associated ophthalmopathy. Journal of endocrinological investigation, 45(2), 235–259. https://doi.org/10.1007/s40618-021-01663-9
Deltour, J. B., d'Assigny Flamen, M., Ladsous, M., Giovansili, L., Cariou, B., Caron, P., Drui, D., & Lebranchu, P. (2020). Efficacy of rituximab in patients with Graves' orbitopathy: A retrospective multicenter nationwide study. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 258(9), 2013–2021. https://doi.org/10.1007/s00417-020-04651-6
Chen, J., Chen, G., & Sun, H. (2021). Intravenous rituximab therapy for active Graves' ophthalmopathy: A meta-analysis. Hormones (Athens, Greece), 20(2), 279–286. https://doi.org/10.1007/s42000-021-00282-6
Perez-Moreiras, J. V., Gomez-Reino, J. J., Maneiro, J. R., Perez-Pampin, E., Romo Lopez, A., Rodríguez Alvarez, F. M., Castillo Laguarta, J. M., Del Estad Cabello, A., Gessa Sorroche, M., España Gregori, E., Sales-Sanz, M., & Tocilizumab in Graves Orbitopathy Study Group (2018). Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant graves orbitopathy: A randomized clinical trial. American journal of ophthalmology, 195, 181–190. https://doi.org/10.1016/j.ajo.2018.07.038
Pérez-Moreiras, J. V., Varela-Agra, M., Prada-Sánchez, M. C., & Prada-Ramallal, G. (2021). Steroid-resistant Graves' orbitopathy treated with tocilizumab in real-world clinical practice: A 9-Year single-center experience. Journal of clinical medicine, 10(4), 706. https://doi.org/10.3390/jcm10040706
Facchini, V., Piccirilli, A., Colangeli, W., Kapitonov, A., Maesa, F., Iachini, I., & Belli, E. (2024). Graves-basedow ophthalmopathy surgical approaches: Open vs endoscopic. Journal of cranio-maxillo-facial surgery: official publication of the European Association for Cranio-Maxillo-Facial Surgery, 52(10), 1063–1071. https://doi.org/10.1016/j.jcms.2024.06.004
Vogel, R., Crockett, R. S., Oden, N., Laliberte, T. W., Molina, L., & Sodium Hyaluronate Ophthalmic Solution Study Group (2010). Demonstration of efficacy in the treatment of dry eye disease with 0.18% sodium hyaluronate ophthalmic solution (vismed, rejena). American journal of ophthalmology, 149(4), 594–601. https://doi.org/10.1016/j.ajo.2009.09.023
Uddin, J. M., & Davies, P. D. (2002). Treatment of upper eyelid retraction associated with thyroid eye disease with subconjunctival botulinum toxin injection. Ophthalmology, 109(6), 1183–1187. https://doi.org/10.1016/s0161-6420(02)01041-2
Mourits, M. P., van Kempen-Harteveld, M. L., García, M. B., Koppeschaar, H. P., Tick, L., & Terwee, C. B. (2000). Radiotherapy for Graves' orbitopathy: Randomised placebo-controlled study. Lancet (London, England), 355(9214), 1505–1509. https://doi.org/10.1016/S0140-6736(00)02165-6
Kim, J. W., Han, S. H., Son, B. J., Rim, T. H., Keum, K. C., & Yoon, J. S. (2016). Efficacy of combined orbital radiation and systemic steroids in the management of Graves' orbitopathy. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 254(5), 991–998. https://doi.org/10.1007/s00417-016-3280-7
Chin, Y. H., Ng, C. H., Lee, M. H., Koh, J. W. H., Kiew, J., Yang, S. P., Sundar, G., & Khoo, C. M. (2020). Prevalence of thyroid eye disease in Graves' disease: A meta-analysis and systematic review. Clinical endocrinology, 93(4), 363–374. https://doi.org/10.1111/cen.14296
Tanda, M. L., Piantanida, E., Liparulo, L., Veronesi, G., Lai, A., Sassi, L., Pariani, N., Gallo, D., Azzolini, C., Ferrario, M., & Bartalena, L. (2013). Prevalence and natural history of Graves' orbitopathy in a large series of patients with newly diagnosed graves' hyperthyroidism seen at a single center. The Journal of clinical endocrinology and metabolism, 98(4), 1443–1449. https://doi.org/10.1210/jc.2012-3873
European Group on Graves' Orbitopathy (EUGOGO), Wiersinga, W. M., Perros, P., Kahaly, G. J., Mourits, M. P., Baldeschi, L., Boboridis, K., Boschi, A., Dickinson, A. J., Kendall-Taylor, P., Krassas, G. E., Lane, C. M., Lazarus, J. H., Marcocci, C., Marino, M., Nardi, M., Neoh, C., Orgiazzi, J., Pinchera, A., Pitz, S., … von Arx, G. (2006). Clinical assessment of patients with Graves' orbitopathy: The European group on Graves' orbitopathy recommendations to generalists, specialists and clinical researchers. European journal of endocrinology, 155(3), 387–389. https://doi.org/10.1530/eje.1.02230
Terwee, C. B., Prummel, M. F., Gerding, M. N., Kahaly, G. J., Dekker, F. W., & Wiersinga, W. M. (2005). Measuring disease activity to predict therapeutic outcome in Graves' ophthalmopathy. Clinical endocrinology, 62(2), 145–155. https://doi.org/10.1111/j.1365-2265.2005.02186.x
Wiersinga W. M. (2013). Smoking and thyroid. Clinical endocrinology, 79(2), 145–151. https://doi.org/10.1111/cen.12222
Manji, N., Carr-Smith, J. D., Boelaert, K., Allahabadia, A., Armitage, M., Chatterjee, V. K., Lazarus, J. H., Pearce, S. H., Vaidya, B., Gough, S. C., & Franklyn, J. A. (2006). Influences of age, gender, smoking, and family history on autoimmune thyroid disease phenotype. The Journal of clinical endocrinology and metabolism, 91(12), 4873–4880. https://doi.org/10.1210/jc.2006-1402
Oeverhaus, M., Winkler, L., Stähr, K., Daser, A., Bechrakis, N., Stöhr, M., Chen, Y., & Eckstein, A. (2023). Influence of biological sex, age and smoking on Graves' orbitopathy - a ten-year tertiary referral center analysis. Frontiers in endocrinology, 14, 1160172. https://doi.org/10.3389/fendo.2023.1160172
Perros, P., Crombie, A. L., Matthews, J. N., & Kendall-Taylor, P. (1993). Age and gender influence the severity of thyroid-associated ophthalmopathy: A study of 101 patients attending a combined thyroid-eye clinic. Clinical endocrinology, 38(4), 367–372. https://doi.org/10.1111/j.1365-2265.1993.tb00516.x
Patel, V. K., Padnick-Silver, L., D'Souza, S., Bhattacharya, R. K., Francis-Sedlak, M., & Holt, R. J. (2022). Characteristics of diabetic and nondiabetic patients with Thyroid eye disease in the united states: A claims-based analysis. Endocrine practice: official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 28(2), 159–164. https://doi.org/10.1016/j.eprac.2021.11.080
Lanzolla, G., Sabini, E., Profilo, M. A., Mazzi, B., Sframeli, A., Rocchi, R., Menconi, F., Leo, M., Nardi, M., Vitti, P., Marcocci, C., & Marinò, M. (2018). Relationship between serum cholesterol and Graves' orbitopathy (GO): A confirmatory study. Journal of endocrinological investigation, 41(12), 1417–1423. https://doi.org/10.1007/s40618-018-0915-z
Mourits, M. P., Prummel, M. F., Wiersinga, W. M., & Koornneef, L. (1997). Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy. Clinical endocrinology, 47(1), 9–14. https://doi.org/10.1046/j.1365-2265.1997.2331047.x
Nicolì, F., Lanzolla, G., Mantuano, M., Ionni, I., Mazzi, B., Leo, M., Sframeli, A., Posarelli, C., Maglionico, M. N., Figus, M., Nardi, M., Marcocci, C., & Marinò, M. (2021). Correlation between serum anti-tsh receptor autoantibodies (TRAbs) and the clinical feature of Graves' orbitopathy. Journal of endocrinological investigation, 44(3), 581–585. https://doi.org/10.1007/s40618-020-01353-y
Currò, N., Covelli, D., Vannucchi, G., Campi, I., Pirola, G., Simonetta, S., Dazzi, D., Guastella, C., Pignataro, L., Beck-Peccoz, P., Ratiglia, R., & Salvi, M. (2014). Therapeutic outcomes of high-dose intravenous steroids in the treatment of dysthyroid optic neuropathy. Thyroid: official journal of the American Thyroid Association, 24(5), 897–905. https://doi.org/10.1089/thy.2013.0445
Wakelkamp, I. M., Baldeschi, L., Saeed, P., Mourits, M. P., Prummel, M. F., & Wiersinga, W. M. (2005). Surgical or medical decompression as a first-line treatment of optic neuropathy in Graves' ophthalmopathy? A randomized controlled trial. Clinical endocrinology, 63(3), 323–328. https://doi.org/10.1111/j.1365-2265.2005.02345.x
Winn, B. J., & Kersten, R. C. (2021). Teprotumumab: Interpreting the clinical trials in the context of Thyroid eye disease pathogenesis and current therapies. Ophthalmology, 128(11), 1627–1651. https://doi.org/10.1016/j.ophtha.2021.04.024
Hwang, C. J., Rebollo, N. P., Mechels, K. B., & Perry, J. D. (2024). Reactivation after teprotumumab treatment for active Thyroid eye disease. American journal of ophthalmology, 263, 152–159. https://doi.org/10.1016/j.ajo.2023.12.001
Fayers, T., & Dolman, P. J. (2011). Validity and reliability of the TED-QOL: A new three-item questionnaire to assess quality of life in thyroid eye disease. The British journal of ophthalmology, 95(12), 1670–1674. https://doi.org/10.1136/bjophthalmol-2011-300487
Delampady, K., Reddy, S. V. B., & Yadav, S. B. (2020). Assessing the quality of life in Indian Graves' orbitopathy patients and validation of Hindi version of GO-QOL questionnaire. Indian journal of ophthalmology, 68(8), 1617–1621. https://doi.org/10.4103/ijo.IJO_2183_19
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Damian Świerczek, Anna Piwko, Szymon Starowicz, Łukasz Stachowicz, Daniel Ściana, Adriana Grądalska
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
